Ionophoric effects of the antitubercular drug bedaquiline

Journal Article (2018)
Author(s)

Kiel Hards (University of Otago)

Duncan G.G. McMillan (TU Delft - BT/Biocatalysis)

Lici A. Schurig-Briccio (University of Illinois)

Robert B. Gennis (University of Illinois)

Holger Lill (Vrije Universiteit Amsterdam)

Dirk Bald (Vrije Universiteit Amsterdam)

Gregory M. Cook (The University of Auckland, University of Otago)

Research Group
BT/Biocatalysis
DOI related publication
https://doi.org/10.1073/pnas.1803723115 Final published version
More Info
expand_more
Publication Year
2018
Language
English
Research Group
BT/Biocatalysis
Issue number
28
Volume number
115
Pages (from-to)
7326-7331
Downloads counter
140
Collections
Institutional Repository
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Bedaquiline (BDQ), an inhibitor of the mycobacterial F1Fo-ATP synthase, has revolutionized the antitubercular drug discovery program by defining energy metabolism as a potent new target space. Several studies have recently suggested that BDQ ultimately causes mycobacterial cell death through a phenomenon known as uncoupling. The biochemical basis underlying this, in BDQ, is unresolved and may represent a new pathway to the development of effective therapeutics. In this communication, we demonstrate that BDQ can inhibit ATP synthesis in Escherichia coli by functioning as a H+/K+ ionophore, causing transmembrane pH and potassium gradients to be equilibrated. Despite the apparent lack of a BDQ-binding site, incorporating the E. coli Fo subunit into liposomes enhanced the ionophoric activity of BDQ. We discuss the possibility that localization of BDQ at F1Fo-ATP synthases enables BDQ to create an uncoupled microenvironment, by antiport-ing H+/K+. Ionophoric properties may be desirable in high-affinity antimicrobials targeting integral membrane proteins.

Files

Proof.pdf
(pdf | 1.95 Mb)
- Embargo expired in 10-01-2019
License info not available